Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of AVB-101 in frontotemporal dementia with progranulin mutations
2023-509444-10-00Phase 2Authorised
- Sponsor
- AviadoBio
- Start
- Feb 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of AVB-101 in Progranulin-Associated Frontotemporal Dementia (FTD-GRN), sponsored by AviadoBio. Primary endpoints: Adverse events and serious adverse events, Vital signs and examination safety changes and 4 more. Planned start Feb 2024; status: authorised.
02
Drugs
AVB-101
03
Conditions
Progranulin-Associated Frontotemporal Dementia (FTD-GRN)
Beyond the preview
Go deeper on 2023-509444-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509444-10-00.